RVPHNCMHealthcare·Biotechnology#513 in industry

Reviva Pharmaceuticals Holdings, Inc.

Reports in 17d· 2026-05-14

-85.5% · 90d

$0.87

-0.03 (-3.42%)

News

(1)

March 2026

Mar 30, 20260 months ago8-KHealthcare

REVIVA PHARMACEUTICALS HOLDINGS, INC. — 8-K Filing

RVPHREVIVA PHARMACEUTICALS HOLDINGS, INC.

# 🧾 What This Document Is This is an 8-K filing, which is like a company's "breaking news" report to the SEC. This specific one includes Reviva's full-year 2025 financial results and a major update on its lead drug, brilaroxazine. The big news? The FDA wants them to run another Phase 3 trial before

Read summaryView on SEC EDGAR

Key Data

Market Cap$11.1M

Open$0.93

Prev Close$0.90

Day Range$0.86 – $0.93

52W Range$0.59 – $23.20

Volume217,601

P/E (TTM)—

EPS$-5.48

Dividend Yield—

Beta0.64

Price Target$58.20(+6593.5%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy5 analysts

Buy 4Hold 1Sell 0

About

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development for respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. The company was founded in 2018 and is headquartered in Cupertino, California.

Healthcare · Biotechnology

14 employees

www.revivapharma.com